Background: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) evaluated the safety and efficacy of bevacizumab plus first-line chemotherapy in a general cohort of patients with mCRC.
) is a humanised mAb that inhibits vascular endothelial growth factor, a key mediator in angiogenesis [1] [2] [3] . In randomised trials in patients with metastatic colorectal cancer (mCRC), bevacizumab improved response rates, overall survival (OS) and progression-free survival (PFS) when combined with the standard chemotherapy treatments of 5-fluorouracil/leucovorin (5-FU/LV) [4] irinotecan plus 5-FU/LV (IFL) [5] and 5-FU/LV + oxaliplatin (FOLFOX) [6] . In addition, combination of bevacizumab with 5-FU/LV [7] and FOLFOX or capecitabine plus oxaliplatin (XELOX) resulted in significantly improved PFS compared with chemotherapy alone [8] .
Most adverse events associated with bevacizumab (hypertension, proteinuria and bleeding) are mild-moderate in severity and are manageable using standard therapies [4, 5, 7, 8] . However, two uncommon, but serious, adverse events have been reported with bevacizumab: arterial thromboembolic events and gastrointestinal (GI) perforation; serious toxic effects related to bevacizumab have an incidence of <5% [9] .
The purpose of the Bevacizumab Expanded Access Trial (First BEAT) was to evaluate the safety and efficacy of bevacizumab plus routine first-line chemotherapy regimens in a broader patient population with mCRC (i.e. in the context of general oncology practice). This article describes the safety and efficacy of bevacizumab-based therapy in 2000 patients followed for up to 43 months (median 21.1 months).
patients and methods

patient population
Patients were included in this open-label, non-comparative trial if they were >18 years old, had histologically confirmed mCRC and were scheduled to start first-line fluoropyrimidine-based chemotherapy. Patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of one or less, life expectancy of >3 months and adequate organ function. Patients provided written informed consent.
Key exclusion criteria were as follows: prior chemotherapy for mCRC (adjuvant chemotherapy for CRC was permitted), surgery within 28 days of starting treatment or surgery anticipated during the study, planned radiotherapy for underlying disease (completed radiotherapy was allowed) and history of malignancy other than mCRC. Patients with uncontrolled hypertension; clinically significant cardiovascular disease, haemorrhagic diathesis or coagulopathy; use of full-dose anticoagulants or thrombolytics; serious non-healing wounds or ulcers and treatment with aspirin (>325 mg/ day) or other medications predisposing to GI ulceration were also excluded.
No formal definition of unresectability for metastatic disease was provided in the study protocol as the exclusion criterion of anticipation of surgery based on investigator assessment was deemed to exclude resectable patients (e.g. for hepatic metastases).
treatment
Eligible patients received bevacizumab plus fluoropyrimidine-based chemotherapy (chosen at the clinician's discretion: single-agent fluoropyrimidine or fluoropyrimidine plus oxaliplatin or irinotecan) until disease progression. The bevacizumab dose was 5 mg/kg every 2 weeks (5-FU-based regimens) or 7.5 mg/kg every 3 weeks (capecitabine-based regimens). Bevacizumab was administered i.v., initially over 90 min. If the first infusion was well tolerated, the second was delivered over 60 min; if the 60-min infusion was well tolerated, all subsequent infusions were delivered over 30 min.
Bevacizumab doses were not reduced or escalated; in cases of serious bevacizumab-related toxicity, bevacizumab was temporarily or permanently suspended. Patients with GI perforation, arterial thromboembolic events, grade 3/4 haemorrhagic events, symptomatic grade 4 thrombosis, grade 4 hypertension or grade 4 proteinuria (nephrotic syndrome) received no further bevacizumab.
assessments Data recorded at baseline included medical history, including hypertension, thromboembolic and atherosclerotic disease, diabetes mellitus, atrial fibrillation, GI ulcers, access device surgery and chronic anticoagulant or aspirin use. At 3-monthly visits, patients underwent physical examination, haematology and serum chemistry, proteinuria within 48 h of bevacizumab and PS evaluation. Other assessments were carried out at the investigator's discretion. Adverse events were assessed using National Cancer Institute-Common Terminology Criteria for Adverse Events (version 3.0). Serious adverse events (SAEs) were those leading to new/prolonged hospitalisation, life-threatening events or death and medically significant events; their relationship to bevacizumab therapy was determined by the investigator. Bevacizumab-associated SAEs were recorded for 6 months after the last study drug administration. Data were collected prospectively on surgical procedures carried out during active study participation and their outcome. Secondary objectives were OS (time from start of first bevacizumab administration to death), time to progression (TTP; time from start of firstline therapy to investigator-assessed progression) and PFS (time from start of first-line therapy to investigator-assessed progression or death, whichever occurred first).
statistical analysis
The planned study enrolment of 2000 patients was to allow assessment of uncommon or rare adverse events following bevacizumab plus chemotherapy in the first-line setting. The intent-to-treat (ITT) population included patients receiving at least one dose of study drug. Adverse events were displayed as standard frequency tables. OS, TTP and PFS were recorded based on the investigator's assessment during 3-monthly clinic visits. Table 1 . Chemotherapy groups were generally well balanced.
Most patients (n = 1589; 83%) received combination chemotherapy in addition to bevacizumab; 16% of patients received monotherapy plus bevacizumab. The most common doublet regimens were FOLFOX (29%), FOLFIRI (26%) and XELOX (18%) (Figure 1 ). Patients were exposed to bevacizumab for an average of 260 days (range 14-993 days).
safety
SAEs were reported in 631 of 1914 patients (33%); SAEs of interest to bevacizumab occurred in 205 of 1914 patients (11%). The most common chemotherapy-related SAEs were diarrhoea (4%) and pyrexia (3%). Grade 3-5 adverse events and SAEs of special interest for bevacizumab were similar across the chemotherapy regimens (Table 2) . Bleeding events in patients with resected and unresected primary tumours were generally mild. GI perforation was reported in 8 of 223 patients (4%) with unresected primary tumours; perforation occurred at the tumour site in three patients: one patient had a history of nonsteroidal anti-inflammatory drug use and GI obstruction, one patient had a history of abdominal/pelvic radiotherapy and one patient had GI obstruction and carcinomatosis. Grade 5 events possibly related to bevacizumab occurred in 38 patients (2%) and included haemorrhage (eight patients, <0.5%); cardiac disorders (cardiac arrest, myocardial infarction) (three patients, <0.5%); respiratory disorders (two patients, <0.5%); venous embolism (11 patients, 1%) and GI perforation (seven patients, 0.4%). In the ITT population, the 60-day mortality was 3%. In patients who underwent surgery with curative intent during active participation in the trial (n = 225, 12%), the rate of reported wound-healing complications was 5% (2% grade 3/4 or SAE). Total bleedings, including non-surgeryrelated bleedings, were reported in 71 patients who underwent surgery (32%), 51 of which were epistaxis (72%); SAE/grade 3-4 events occurred in six patients (2.7%) and included one serious epistaxis event. Surgery defined as curative hepatic metastasectomy was carried out in 145 patients (7.6% of the overall population) and was R0 in 114 patients (6%). The rate of curative hepatic metastasectomy was 10.4% in patients treated with oxaliplatin (99 of 949 patients) and 6.5% in patients treated with irinotecan (43 of 662 patients); R0 rates were 8.0% and 5.1%, respectively. In patients with metastatic disease confined to the liver at baseline (n = 704), curative-intent hepatic metastasectomy rates reached 15.2% (n = 107) overall and was R0 in 85 patients (12.1%). The rate was 20.3% for those treated with oxaliplatin (71 of 350 patients) and 14.3% for those treated with irinotecan (33 of 230 patients); R0 resection rates were 15.4% (n = 54) and 11.7% (n = 27), respectively. Two-year OS was 89% in patients with curative-intent hepatic metastasectomy and 94% in patients with curative R0 hepatic metastasectomy versus 54% in all patients with disease confined to the liver.
discussion
This final analysis of the BEAT study shows that the safety profile of bevacizumab in clinical practice is consistent with previous observations in prospective randomised clinical trials [5, 6, 10] and an observational registry study in the United States [11] . The similar rates of bevacizumab-related adverse events with the different chemotherapy regimens used in this trial indicate that bevacizumab can be used with any of the chemotherapy regimens used routinely in clinical practice.
It is noteworthy that the incidences of adverse events of special interest for bevacizumab reported in this programme were lower than reported in previous randomised trials. For example, grade 3-5 hypertension and hypertension as an SAE had an incidence of 5% in the present trial but was reported in 11% (control 2%) and 16% (control 3%) of patients in the studies by Hurwitz et al. [5] and Kabbinavar et al. [12] , respectively. This reduced incidence may be a result of increasing awareness of the toxicity profile of bevacizumab leading to better patient selection and earlier intervention for issues such as hypertension. In general, bleeding events were rather mild; serious bleeding was uncommon and may be an indicator of GI perforation, which occurred in only 4% of the 223 patients with unresected tumours. The absence of a control group in the BEAT study makes it difficult to speculate as to the role of bevacizumab in these events. Overall, the safety profile of bevacizumab use in this broad patient population appears to be similar to that previously observed in controlled clinical studies.
Evaluation of the safety of bevacizumab in combination with first-line chemotherapy for mCRC in a large observational registry study in the United States (BRiTE) revealed similar incidences of adverse events to those reported in BEAT, although slightly different reporting methods were used [13] . The BRiTE study reported wound-healing complications in 1% versus 4% in BEAT, arterial thromboembolic events in 2% versus 1%, grade 3/4 bleeding in 3% versus 2% and GI perforation in 2% for both studies. In BRiTE, serious (grade 3/4) postoperative wound-healing complications occurred in 4% of patients undergoing any type of surgery after starting treatment with first-line bevacizumab plus chemotherapy [14] . Patients requiring surgery within 14 days of the last bevacizumab dose were at higher risk (7%) of developing wound-healing complications; those undergoing surgery >60 days after the last bevacizumab dose had a lower risk (2%), which is the same as in BEAT (grade 3/4 SAE events in 2%), and only slightly higher than reported elsewhere (1%) [15] .
Median PFS was 10.8 months in BEAT, consistent with reports from randomised trials of first-line bevacizumab in mCRC (9.0-10.6 months) [5, 7, 8, 12] and BRiTE (9.9 months; (2) 10 (2) 3 (1) 34 (2) 6 (2) 10 (2) 9 (2) 3 ( Annals of Oncology original article 95% CI 9.5-10.3 months) [16] . As expected, median PFS was lower when bevacizumab was combined with 5-FU or capecitabine monotherapy versus doublet regimens. The median OS of 22.7 months (95% CI 21.7-23.8 months) in BEAT was similar to values reported in randomised trials (16.6-21.5 months) [5, 7, 8, 12] and BRiTE (23.5 months; 95% CI 22.5-25.1 months) [16] . Median PFS, TTP and OS were consistent across the doublet regimens in BEAT, suggesting that the effectiveness of bevacizumab is not related to the chemotherapy regimen used. Our data also confirm that hepatic metastasectomy after bevacizumab plus chemotherapy is feasible and safe. R0 resection rates achieved in these patients-originally deemed unresectable-indicate that randomised trials evaluating the use of bevacizumab before resection of liver metastases are warranted. It should be noted that formal, multidisciplinary assessment of resectability was not required before entry into the BEAT study. A more rigorous assessment process is likely to have identified patients with resectable disease and therefore reduced the number of patients with resectable tumours after treatment. Our data also appear to indicate that the combination of bevacizumab and oxaliplatin-based chemotherapy is more successful in tumour downsizing than irinotecan combinations, as a substantial difference was seen in resectability rates in these groups. It is possible, however, that investigators in the BEAT study chose to prescribe oxaliplatinrather than irinotecan-based chemotherapy for patients with potentially resectable tumours, leading to a possible imbalance in the two groups of patients.
Some limitations of this study should be considered. Estimation of PFS is limited by the fact that assessment of disease progression was not carried out at protocol-specified intervals and that progression was not independently assessed. Although BEAT was designed to be representative of general oncology practice, eligible patients had to have an ECOG PS of zero or one. While some physicians avoid aggressively treating patients with poor PS, many prescribe combination regimens for these patients. Therefore, the BEAT population may not be truly reflective of a community-based practice. Data on surgery with curative intent were collected prospectively but are limited because of the lack of protocoldefined resectability criteria; the definition of resectability was made by the investigators. Finally, this was an observational study and not a randomised clinical trial, therefore the possibility of investigator bias must be considered. Ellis and Haller have, however, pointed out that observational studies are important tools that allow the development of new hypotheses, which can then be tested in prospective randomised trials [17] .
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